2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Abstract Number: 762

Pragmatic Treatment of Patients with Systemic Lupus Erythematosus with Rituximab: Long-Term Effects on Serum Immunoglobulins
Abstract Number: 763

Rituximab As a Corticosteroid-Sparing Agent in Patients with Systemic Lupus Erythematosus
Abstract Number: 764

Atacicept: Integrated Safety Profile from Phase II Randomized Placebo-Controlled Studies in Autoimmune Diseases
Abstract Number: 765

High Baseline B Lymphocyte Stimulator (BLyS) Levels Predict Response While Smoking and Organ Damage at Baseline Predict Failure to Belimumab in Three Swedish Clinical Practice Settings
Abstract Number: 766

Withdrawal of Mycophenolate Mofetil after Maintenance Treatment of SLE Nephritis Associated with Renal Relapse
Abstract Number: 767

Hydroxychloroquine Induced Retinopathy in SLE
Abstract Number: 768

7-Year Safety and Efficacy of Belimumab in Patients with Systemic Lupus Erythematosus
Abstract Number: 769

Response to Belimumab in SLE Patients with High Disease Activity: Data from a Multicentric Clinical-Practice Based Study Cohort
Abstract Number: 770

Introducing a Novel SLE-Specific IFN-I Inhibitor CNTO 6358: Laying the Groundwork for Precision Medicine in Lupus
Abstract Number: 771

Preventive Effects of Glucocorticoids on Progression of Atherosclerosis in Japanese Patients with SLE
Abstract Number: 772

Effect of HMG-CoA Reductase Inhibitor Drugs (Statins) on Systemic Lupus Erythematosus Disease Activity: A Systematic Review and Meta-Analysis
Abstract Number: 773

Risk Factors for Severe Infections in Rituximab Treated Patients: Comparison of Systemic Lupus Erythematosus and Inflammatory Myositis
Abstract Number: 774

BIIB059, an Anti-BDCA2 Monoclonal Antibody, Demonstrates Acceptable Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamic (PD) Effects in a Phase 1 Study with Single Ascending Doses (SAD) in Healthy Volunteers
Abstract Number: 775

Evaluation of Use of Belimumab in Clinical Practice Settings: Results in Argentina
Abstract Number: 776

Eurolupus and Low Steroid Regimen in Proliferative Lupus Nephritis: Retrospective Evaluation of 38 Patients in the Black Population of Martinique

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].